Medicinal Uses of Marijuana and Cannabinoids

References

• Abrams, D. I., Hilton, J. F., Leiser, R. J., Shade, S. B., Elbeik, T. A., Aweeka, F. T., Benowitz, N. L., Bredt, B. M., Kosel, B., Aberg, J. A., Deeks, S. G., Mitchell, T. F., Mulligan, K., Bacchetti, P., McCune, J. M., and Schambelan, M. 2003. Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann. Intern. Med. 139(4): 258–266.
   PubMed Web of Science ®Google Scholar
• Abrams, D. I., Jay, C. A., Shade, S. B., Vizoso, H., Reda, H., Press, S., Kelly, M. E., Rowbotham, M. C., and Petersen, K. L. 2007. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 68(7): 515–521.
   PubMed Web of Science ®Google Scholar
• Ahmedzai, S., Carlyle, D. L., Clader, I. T., and Moran, F. 1983. Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. Br. J. Cancer 48: 657–663.
   PubMed Web of Science ®Google Scholar
• Allsop, D., Copeland, J., Lintzeris, N., Dunlop, A., Montebello, M., Sadler,  , Rivas, G. R., Holland, R. M., Muhleisen, P., Norberg, M. M., Booth, J., and McGregor, I. S. 2014. Nabiximols as an agonist replacement therapy during cannabis withdrawal. JAMA Psychiatry 71(3): 281.
   PubMed Web of Science ®Google Scholar
• Aragona, M., Onesti, E., Tomassini, V., Conte, A., Gupta, S., Gilio, F., Pantano, P., Pozzilli, C., and Inghilleri, M. 2009. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study. Clin. Neuropharmacol. 32(1): 41–47.
   PubMed Web of Science ®Google Scholar
• Beal, J. E., Olson, R., Laubenstein, L., Morales, J. P., Bellman, P., Yangco, B., Lefkowitz, L., Plasse, T. F., and Shepard, K. V. 1995. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J. Pain Symptom. Manage. 10(2): 89–97.
   PubMed Web of Science ®Google Scholar
• Beaulieu, P. 2006. Effects of nabilone, a synthetic cannabinoid, on postoperative pain. Can. J. Anaesth. 53(8): 769–775.
   PubMed Web of Science ®Google Scholar
• Bergamaschi, M. M., Queiroz, R. H., Chagas, M. H., de Oliveira, D. C., De Martinis, B. S., Kapczinski, F., Quevedo, J., Roesler, R., Schröder, N., Nardi, A. E., Martín-Santos, R., Hallak, J. E., Zuardi, A. W., and Crippa, J. A. 2011. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology 36(6): 1219–1226.
   PubMed Web of Science ®Google Scholar
• Bergamaschi, M., Queiroz, R., Chagas, M., de Oliveira, D., De Martinis, B., Kapczinski, F. Quevedo, J., Roesler, R., Schröder, N., Nardi, A. E., Martín-Santos, R., Hallak, J. E., Zuardi, A. W., and Crippa, J. A. 2011. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology 36(6): 1219–1226.
   PubMed Web of Science ®Google Scholar
• Berman, J. S., Symonds, C., and Birch, R. 2004. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomized controlled trial. Pain 112(3): 299–306.
   PubMed Web of Science ®Google Scholar
• Blake, D. R., Robson, P., Ho, M., Jubb, R. W., and McCabe, C. S. 2006. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford) 45(1): 50–52.
   PubMed Web of Science ®Google Scholar
• Brisbois, T. D., de Kock, I. H., Watanabe, S. M., Mirhosseini, M., Lamoureux, D. C., Chasen, M., Macdonald, N., Baracos, V. E., and Wismer, W. V. 2011. Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Ann. Oncol. 22(9): 2086–2093.
   PubMed Web of Science ®Google Scholar
• Buggy, D. J., Toogood, L., Maric, S., Sharpe, P., Lambert, D. G., and Rowbotham, D. J. 2003. Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain. Pain 106(1–2): 169–172.
   PubMed Web of Science ®Google Scholar
• Carroll, C. B., Bain, P. G., Teare, L., Liu, X., Joint, C., Wroath, C., Parkin, S. G., Fox, P., Wright, D., Hobart, J., and Zajicek, J. P. 2004. Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology 63(7): 1245–1250.
   PubMed Web of Science ®Google Scholar
• Chagas, M. H., Zuardi, A. W., Tumas, V., Pena-Pereira, M. A., Sobreira, E. T., Bergamaschi, M. M., dos Santos, A. C., Teixeira, A. L., Hallak, J. E., and Crippa, J. A. 2014. Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial. J. Psychopharmacol. 28(11): 1088–1098.
   PubMed Web of Science ®Google Scholar
• Chagas, M., Zuardi, A., Tumas, V., Pena-Pereira, M., Sobreira, E., Bergamaschi, M., dos Santos, A. C., Teixeira, A. L., Hallak, J. E., and Crippa, J. A. 2014. Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial. J. Psychopharmacol. 28(11): 1088–1098.
   PubMed Web of Science ®Google Scholar
• Chan, H. S., Correia, J. A., and MacLeod, S. M. 1987. Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial. Pediatrics 79: 946–952.
   PubMed Web of Science ®Google Scholar
• Chang, A. E., Shiling, D. J., Stillman, R. C., Goldberg, N. H., Seipp, C. A., and Barofsky, I. 1979. Delta-9-tetrahydrocannabinol as an antiemetics in cancer patients receiving high-dose methotrexate. Ann. Intern. Med. 91: 819–824.
   PubMed Web of Science ®Google Scholar
• Chang, A. E., Shiling, D. J., Stillman, R. C., Goldberg, N. H., Seipp, C. A., Barofsky, I., and Rosenberg, S. A. 1981. A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. Cancer 47: 1746–1751.
   PubMed Web of Science ®Google Scholar
• Clifford, D. B. 1983. Tetrahydrocannabinol for tremor in multiple sclerosis. Ann. Neurol. 13: 669–671.
   PubMed Web of Science ®Google Scholar
• Collin, C., Davies, P., Mutiboko, I. K., and Ratcliffe, S., for the Sativex Spasticity in MS Study Group. 2007. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur. J. Neurol. 14(3): 290–296.
   PubMed Web of Science ®Google Scholar
• Collin, C., Ehler, E., Waberzinek, G., Alsindi, Z., Davies, P., and Powell, K. 2010. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol. Res. 32(5): 451–459.
   PubMed Web of Science ®Google Scholar
• Colls, B. M., Ferry, D. G., Gray, A. J., Harvey, V. J., and McQueen, E. G. 1980. The antiemetic activity of tetrahydrocanabinol versus metoclopramide and thiethylperazine in patients undergoing cancer chemotherapy. N. Z. Med. J. 91: 449–451.
   PubMed Web of Science ®Google Scholar
• Consroe, P., Sandyk, R., and Snider, S. R. 1986. Open label evaluation of cannabidiol in dystonic movement disorders. Int. J. Neurosci. 30(4): 277–282.
   PubMed Web of Science ®Google Scholar
• Conte, A., Bettolo, C. M., Onesti, E., Frasca, V., Iacovelli, E., Gilio, F., Giacomelli, E., Gabriele, M., Aragona, M., Tomassini, V., Pantano, P., Pozzilli, C., and Inghilleri, M. 2009. Cannabinoid-induced effects on the nociceptive system: a neurophysiological study in patients with secondary progressive multiple sclerosis. Eur. J. Pain. 13(5): 472–477.
   PubMed Web of Science ®Google Scholar
• Corey-Bloom, J., Wolfson, T., Gamst, A., Jin, S., Marcotte, T., Bentley, H., and Gouaux, B. 2012. Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. CMAJ 184(10): 1143–1150.
   PubMed Web of Science ®Google Scholar
• Côté, M., Trudel, M., Wang, C., and Fortin, A. 2015. Improving quality of life with nabilone during radiotherapy treatments for head and neck cancers: a randomized double-blind placebo-controlled trial. Ann. Otol. Rhinol. Laryngol. [in press].
   PubMed Web of Science ®Google Scholar
• Crawford, S. M. and Buckman, R. 1986. Nabilone and metoclopramide in the treatment of nausea and vomiting due to cisplatinum: a double blind study. Med. Oncol. Tumor Pharmacother. 3: 39–42.
   PubMedGoogle Scholar
• Crippa, J. A., Derenusson, G. N., Ferrari, T. B., Wichert-Ana, L., Duran, F. L., Martin-Santos, R., Simões, M. V., Bhattacharyya, S., Fusar-Poli, P., Atakan, Z., Santos Filho, A., Freitas-Ferrari, M. C., McGuire, P. K., Zuardi, A. W., Busatto, G. F., and Hallak, J. E. 2011. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J. Psychopharmacol. 25(1): 121–130.
   PubMed Web of Science ®Google Scholar
• Crippa, J., Derenusson, G., Ferrari, T., Wichert-Ana, L., Duran, F., Martin-Santos, R., Simões, M. V., Bhattacharyya, S., Fusar-Poli, P., Atakan, Z., Santos Filho, A., Freitas-Ferrari, M. C., McGuire, P. K., Zuardi, A. W., Busatto, G. F., and Hallak, J. E. 2011. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J. Psychopharmacol. 25(1): 121–130.
   PubMed Web of Science ®Google Scholar
• Cunha, J. M., Carlini, E. A., Pereira, A. E., Ramos, O. L., Pimentel, C., Gagliardi, R., Sanvito, W. L., Lander, N., and Mechoulam, R. 1980. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 21(3): 175–185.
   PubMed Web of Science ®Google Scholar
• Cunha, J. M., Carlini, E. A., Pereira, A. E., Ramos, O. L., Pimentel, C., Gagliardi, R., Sanvito, W. L., Lander, N., and Mechoulam, R. 1980. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 21(3): 175–185.
   PubMed Web of Science ®Google Scholar
• Dalzell, A. M., Bartlett, H., and Lilleyman, J. S. 1986. Nabilone: an alternative antiemetic for cancer chemotherapy. Arch. Dis. Child. 61: 502–505.
   PubMed Web of Science ®Google Scholar
• Das, R., Kamboj, S., Ramadas, M., Yogan, K., Gupta, V., Redman, E., Curran, H. V., and Morgan, C. J. 2013. Cannabidiol enhances consolidation of explicit fear extinction in humans. Psychopharmacology 226(4): 781–792.
   PubMed Web of Science ®Google Scholar
• Devinsky, O., Marsh, E., Friedman, D., Thiele, E., Laux, L., Sullivan, J., Miller, I., Flamini, R., Wilfong, A., Filloux, F., Wong, M., Tilton, N., Bruno, P., Bluvstein, J., Hedlund, J., Kamens, R., Maclean, J., Nangia, S., Singhal, N. S., Wilson, C. A., Patel, A., and Cilio, M. R. 2015. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. [in press].
   PubMed Web of Science ®Google Scholar
• D'Souza, D. C., Abi-Saab, W. M., Madonick, S., Forselius-Bielen, K., Doersch, A., Braley, G., Gueorguieva, R., Cooper, T. B., and Krystal, J. H. 2005. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol. Psychiatry 57(6): 594–608.
   PubMed Web of Science ®Google Scholar
• Duran, M., Pérez, E., Abanades, S., Vidal, X., Saura, C., Majem, M., Arriola, E., Rabanal, M., Pastor, A., Farré, M., Rams, N., Laporte, J. R., and Capellà, D. 2010. Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. Br. J. Clin. Pharmacol. 70(5): 656–663.
   PubMed Web of Science ®Google Scholar
• Einhorn, L. H., Nagy, C., Furnas, B., and Williams, S. D. 1981. Nabilone: an effective antiemetic in patients receiving cancer chemotherapy. J. Clin. Pharmacol. 21(8–9 Suppl): 64–69.
   Web of Science ®Google Scholar
• Ellis, R. J., Toperoff, W., Vaida, F., van den Brande, G., Gonzales, J., Gouaux, B., Bentley, H., and Atkinson, J. H. 2009. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology 34(3): 672–680.
   PubMed Web of Science ®Google Scholar
• ElSohly, M. 2016, November. My Journey with Cannabis: Past, Present and Future. Presentation at the SACM Conference, Basel, Switzerland.
   Google Scholar
• Engels, F. K., de Jong, F. A., Sparreboom, A., Mathot, R. A., Loos, W. J., Kitzen, J. J., de Bruijn, P., Verweij, J., and Mathijssen, R. H. 2007. Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel. Oncologist 12(3): 291–300.
   PubMed Web of Science ®Google Scholar
• Englund, A., Atakan, Z., Kralj, A., Tunstall, N., Murray, R., and Morrison, P. 2015. The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: a placebo-controlled, double-blind, crossover pilot trial. J. Psychopharmacol. [in press].
   PubMed Web of Science ®Google Scholar
• Esfandyari, T., Camilleri, M., Busciglio, I., Burton, D., Baxter, K., and Zinsmeister, A. R. 2007. Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebo-controlled study. Am. J. Physiol. Gastrointest. Liver. Physiol. 293(1): 137–145.
   Web of Science ®Google Scholar
• Esfandyari, T., Camilleri, M., Ferber, I., Burton, D., Baxter, K., and Zinsmeister, A. R. 2006. Effect of a cannabinoid agonist on gastrointestinal transit and postprandial satiation in healthy human subjects: a randomized, placebo-controlled study. Neurogastroenterol. Motil. 18(9): 831–838.
   PubMed Web of Science ®Google Scholar
• Fankhauser, M. 2003. Haschisch als Medikament: Zur Bedeutung von cannabis sativa in der westlichen Medizin. SGGP, Schweizerischer Apothekerverein, Liebefeld (Schweiz).
   Google Scholar
• Fox, P., Bain, P. G., Glickman, S., Carroll, C., and Zajicek, J. 2004. The effect of cannabis on tremor in patients with multiple sclerosis. Neurology 62(7): 1105–1109.
   PubMed Web of Science ®Google Scholar
• Fox, S. H., Kellett, M., Moore, A. P., Crossman, A. R., and Brotchie, J. M. 2002. Randomized, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Mov. Disord. 17(1): 145–149.
   PubMed Web of Science ®Google Scholar
• Frank, B., Serpell, M. G., Hughes, J., Matthews, J. N., and Kapur, D. 2008. Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomized, crossover, double blind study. BMJ 336(7637): 199–201.
   PubMed Web of Science ®Google Scholar
• Freeman, R. M., Adekanmi, O., Waterfield, M. R., Waterfield, A. E., Wright, D., and Zajicek, J. 2006. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomized placebo-controlled trial (CAMS-LUTS). Int. Urogynecol. J. Pelvic. Floor. Dysfunct. 17(6): 636–641.
   PubMed Web of Science ®Google Scholar
• Frytak, S., Moertel, C. G., O'Fallon, J. R., Rubin, J., Creagan, E. T., and O'Connnell, M. J. 1979. Delta-9-tetrahydrocannabinol as an antiemetics for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. Ann. Intern. Med. 91: 825–830.
   PubMed Web of Science ®Google Scholar
• Gaoni, Y. and Mechoulam, R. 1964. Isolation, structure, and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 86: 1646–1647.
   Web of Science ®Google Scholar
• George, M., Pejovic, M. H., Thuaire, M., Kramar, A., and Wolff, J. P. 1983. Randomized comparative trial of a new anti-emetic: nabilone, in cancer patients treated with cisplatin. Biomed. Pharmacother. 37: 24–27.
   PubMed Web of Science ®Google Scholar
• Gralla, R. J., Tyson, L. B., Bordin, L. A., Clark, R. A., Kelsen, D. P., and Kris, M. G. 1984. Antiemetic therapy: a review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannabinol. Cancer Treat. Rep. 68: 163–172.
   PubMedGoogle Scholar
• Grant, J. E., Odlaug, B. L., Chamberlain, S. R., and Kim, S. W. 2011. Dronabinol, a cannabinoid agonist, reduces hair pulling in trichotillomania: a pilot study. Psychopharmacology (Berl). 218(3): 493–502.
   PubMed Web of Science ®Google Scholar
• Grant, J. E., Odlaug, B. L., Chamberlain, S. R., and Kim, S. W. 2011. Dronabinol, a cannabinoid agonist, reduces hair pulling in trichotillomania: a pilot study. Psychopharmacology (Berl). 218(3): 493–502.
   PubMed Web of Science ®Google Scholar
• Greenberg, H. S., Werness, S. A. S., Pugh, J. E., Andrus, R. O., Anderson, D. J., and Domino, E. F. 1994. Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Clin. Pharmacol. Ther. 55: 324–328.
   PubMed Web of Science ®Google Scholar
• Grotenhermen, F. 2005. Cannabinoids. Curr. Drug. Targets. CNS. Neurol. Disord. 4(5): 507–530.
   PubMedGoogle Scholar
• Grotenhermen, F. 2014. Non-psychological adverse effects. In: Handbook of Cannabis. pp. 674–691. Pertwee, R., Ed., Oxford University Press, Oxford.
   Google Scholar
• Grotenhermen, F., Berger, M., and Gebhardt, K. 2015. Cannabidiol (CBD): Ein cannabishaltiges Compendium. Nachtschatten Verlag, Solothurn (Schweiz).
   Google Scholar
• Grotenhermen, F. and Müller-Vahl, K. 2012. The therapeutic potential of cannabis and cannabinoids. Dtsch. Arztebl. Int. 109(29-30): 495-501.
   Google Scholar
• Hagenbach, U., Luz, S., Ghafoor, N., Berger, J. M., Grotenhermen, F., Brenneisen, R., and Mäder, M. 2007. The treatment of spasticity with Delta9-tetrahydrocannabinol in persons with spinal cord injury. Spinal Cord. 45(8): 551–562.
   PubMed Web of Science ®Google Scholar
• Haney, M., Gunderson, E. W., Rabkin, J., Hart, C. L., Vosburg, S. K., Comer, S. D., and Foltin, R. W. 2007. Dronabinol and marijuana in HIV-positive marijuana smokers. Caloric intake, mood, and sleep. J. Acquir. Immune. Defic. Syndr. 45(5): 545–554.
   PubMed Web of Science ®Google Scholar
• Haney, M., Rabkin, J., Gunderson, E., and Foltin, R. W. 2005. Dronabinol and marijuana in HIV(+) marijuana smokers: acute effects on caloric intake and mood. Psychopharmacology (Berl) 181(1): 170–178.
   PubMed Web of Science ®Google Scholar
• Hanigan, W. C., Destree, R., and Truong, X. T. 1986. The effect of Δ9-THC on human spasticity. Clinic. Pharmacol. Ther. 39: 198.
   Web of Science ®Google Scholar
• Hazekamp, A., Ware, M. A., Muller-Vahl, K. R., Abrams, D., and Grotenhermen, F. 2013. The medicinal use of cannabis and cannabinoids–an international cross-sectional survey on administration forms. J. Psychoactive Drugs 45(3): 199–210.
   PubMed Web of Science ®Google Scholar
• Herman, T. S., Einhorn, L. H., Jones, S. E., Nagy, C., Chester, A. B., and Dean, J. C. 1979. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N. Engl. J. Med. 300: 1295–1297.
   PubMed Web of Science ®Google Scholar
• Hindocha, C., Freeman, T. P., Schafer, G., Gardener, C., Das, R. K., Morgan, C. J., and Curran, H. V. 2015. Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomized, double-blind, placebo-controlled study in cannabis users. Eur. Neuropsychopharmacol. 25(3): 325–334.
   PubMed Web of Science ®Google Scholar
• Holdcroft, A., Maze, M., Dore, C., Tebbs, S., and Thompson, S. 2006. A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management. Anesthesiology 104(5): 1040–1046.
   PubMed Web of Science ®Google Scholar
• Holdcroft, A., Maze, M., Dore, C., Tebbs, S., and Thompson, S. 2006. A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management. Anesthesiology 104(5): 1040–1046.
   PubMed Web of Science ®Google Scholar
• Holdcroft, A., Smith, M., Jacklin, A., Hodgson, H., Smith, B., Newton, M., and Evans, F. 1997. Pain relief with oral cannabinoids in familial Mediterranean fever. Anaesthesia 52: 483–488.
   PubMed Web of Science ®Google Scholar
• Hollister, L. E. 1999. Interactions of marihuana and Δ9-THC with other drugs. In: Marihuana and Medicine. pp. 273–277. Nahas, G., Sutin, K. M., Harvey, D. J., and Agurell, S., Eds., Humana Press, Totowa, NJ.
   Google Scholar
• Hutcheon, A. W., Palmer, J. B., Soukop, M., Cunningham, D., McArdle, C., and Welsh, J. 1983. A randomized multicentre single blind comparison of a cannabinoid anti-emetic (levonantradol) with ychlorpromazine in patients receiving their first cytotoxic chemotherapy. Eur. J. Cancer. Clin. Oncol. 19: 1087–1090.
   PubMedGoogle Scholar
• Issa, M., Narang, S., Jamison, R., Michna, E., Edwards, R., Penetar, D., and Wasan, A. D. 2014. The subjective psychoactive effects of oral dronabinol studied in a randomized, controlled crossover clinical trial for pain. Clin. J. Pain. 30(6): 472–478.
   PubMed Web of Science ®Google Scholar
• Jain, A. K., Ryan, J. R., McMahon, F. G., and Smith, G. 1981. Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. J. Clin. Pharmacol. 21(suppl 8–9): 320–326.
   Web of Science ®Google Scholar
• Jatoi, A., Windschitl, H. E., Loprinzi, C. L., Sloan, J. A., Dakhil, S. R., Mailliard, J. A., Pundaleeka, S., Kardinal, C. G., Fitch, T. R., Krook, J. E., Novotny, P. J., and Christensen, B. 2002. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J. Clin. Oncol. 20(2): 567–573.
   PubMed Web of Science ®Google Scholar
• Jetly, R., Heber, A., Fraser, G., and Boisvert, D. 2015. The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: a preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology 51: 585–588.
   PubMed Web of Science ®Google Scholar
• Jiang, R., Yamaori, S., Okamoto, Y., Yamamoto, I., and Watanabe, K. 2013. Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19. Drug. Metab. Pharmacokinet. 28(4): 332–338.
   PubMed Web of Science ®Google Scholar
• Jochimsen, P. R., Lawton, R. L., VerSteeg, K., and Noyes, Jr. R. 1978. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clin. Pharmacol. Ther. 24: 223–227.
   PubMed Web of Science ®Google Scholar
• Johansson, R., Kilkku, P., and Groenroos, M. 1982. A double-blind, controlled trial of nabilone vs prochlorperazine for refractory emesis induced by cancer chemotherapy. Cancer Treat. Rev. 9: 25–33.
   PubMed Web of Science ®Google Scholar
• Johnson, J. R., Burnell-Nugent, M., Lossignol, D., Ganae-Motan, E. D., Potts, R., and Fallon, M. T. 2010. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J. Pain Symptom. Manage. 39(2): 167–179.
   PubMed Web of Science ®Google Scholar
• Johnson, J. R., Lossignol, D., Burnell-Nugent, M., and Fallon, M. T. 2013. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. J. Pain Symptom. Manage. 46(2): 207–218.
   PubMed Web of Science ®Google Scholar
• Jones, S. E., Durant, J. R., Greco, F. A., and Robertone, A. 1982. A multi-institutional phase III study of nabilone vs placebo in chemotherapy-induced nausea and vomiting. Cancer Treat. Rev. 9: 45–48.
   PubMed Web of Science ®Google Scholar
• Karst, M., Salim, K., Burstein, S., Conrad, I., Hoy, L., and Schneider, U. 2003. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA 290(13): 1757–1762.
   PubMed Web of Science ®Google Scholar
• Katona, S., Kaminski, E., Sanders, H., and Zajicek, J. 2005. Cannabinoid influence on cytokine profile in multiple sclerosis. Clin. Exp. Immunol. 140(3): 580–585.
   PubMed Web of Science ®Google Scholar
• Kavi, R. B., De Ridder, D., Constantinescu, C. S., Stott, C. G., and Fowler, C. J. 2010. Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult. Scler. 16(11): 1349–1359.
   PubMed Web of Science ®Google Scholar
• Killestein, J., Hoogervorst, E. L., Reif, M., Kalkers, N. F., Van Loenen, A. C., Staats, P. G., Gorter, R. W., Uitdehaag, B. M., and Polman, C. H. 2002. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 58(9): 1404–1407.
   PubMed Web of Science ®Google Scholar
• Klooker, T., Leliefeld, K., Van Den Wijngaard, R., and Boeckxstaens, G. 2011. The cannabinoid receptor agonist delta-9-tetrahydrocannabinol does not affect visceral sensitivity to rectal distension in healthy volunteers and IBS patients. Neurogastroenterol. Motil. 23(1): 30–e2.
   PubMed Web of Science ®Google Scholar
• Kluin-Nelemans, J. C., Nelemans, F. A., Meuwissen, O. J. A. T. h., and Maes, R. A. A. 1979. Δ9-tetrahydrocannabinol (THC) as an antiemetic in patients treated with cancer chemotherapy; a double-blind cross-over trial against placebo. N. Engl. J. Med. 21: 338–340.
   Google Scholar
• Kosel, B. W., Aweeka, F. T., Benowitz, N. L., Shade, S. B., Hilton, J. F., Lizak, P. S., and Abrams, D. I. 2002. The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. AIDS 16(4): 543–550.
   PubMed Web of Science ®Google Scholar
• Kraft, B., Frickey, N. A., Kaufmann, R. M., Reif, M., Frey, R., Gustorff, B., and Kress, H. G. 2008. Lack of analgesia by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers. Anesthesiology 109(1): 101–110.
   PubMed Web of Science ®Google Scholar
• Lane, M., Vogel, C. L., Ferguson, J., Krasnow, S., Saiers, J. L., and Hamm, J. 1991. Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. J. Pain Symptom. Manage. 6: 352–359.
   PubMed Web of Science ®Google Scholar
• Langford, R. M., Mares, J., Novotna, A., Vachova, M., Novakova, I., Notcutt, W., and Ratcliffe, S. 2013. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J. Neurol. 260(4): 984–997.
   PubMed Web of Science ®Google Scholar
• Levin, F., Mariani, J., Brooks, D., Pavlicova, M., Cheng, W., and Nunes, E. 2011. Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 116(1–3): 142–150.
   PubMed Web of Science ®Google Scholar
• Levitt, M. 1982. Nabilone vs placebo in the treatment of chemotherapy-induced nausea and vomiting in cancer patients. Cancer Treat. Rev. 9(suppl B): 49–53.
   PubMed Web of Science ®Google Scholar
• Levitt, M., Faiman, C., Hawks, R., and Wilson, A. 1984. Randomized double blind comparison of delta-9-tetrahydroicannabinol (THC) and marijuana as chemotherapy antiemetics. Proc. Am. Med. Soc. Clin. Onc. 3: 91.
   Google Scholar
• Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., and Koethe, D. 2012. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl. Psychiatry. 20:(2): e94.
   Web of Science ®Google Scholar
• Leweke, F., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C., Hoyer, C., Klosterkötter, J., Hellmich, M., and Koethe, D. 2012. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl. Psychiatry. 2(3): e94.
   PubMed Web of Science ®Google Scholar
• Lindstrom, P., Lindblom, U., and Boreus, L. 1992. Lack of effect of cannabidiol in sustained neuropathia. Paper presented at '87 International Conference on Cannabis, Melbourne, September 2–4, 1987. Cited from: Consroe, P. and Sandyk, R. Potential role of cannabinoids for therapy of neurological disorders. In: Marijuana/Cannabinoids. Neurobiology and Neurophysiology. pp. 459–524. Murphy, L. and Bartke, A., Eds., CRC Press, Boca Raton, FL.
   Google Scholar
• Loewe, S. 1950. Cannabiswirkstoffe und Pharmakologie der Cannabinole. Arch. Exp. Pathol. Pharmakol. 211: 175–193.
   PubMedGoogle Scholar
• Lynch, M., Cesar-Rittenberg, P., and Hohmann, A. 2014. A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. J. Pain Symptom. Manage. 47(1): 166–173.
   PubMed Web of Science ®Google Scholar
• Maccarrone, M., Bab, I., Bíró, T., Cabral, G. A., Dey, S. K., Di Marzo, V., Konje, J. C., Kunos, G., Mechoulam, R., Pacher, P., Sharkey, K. A., and Zimmer, A. 2015. Endocannabinoid signaling at the periphery: 50 years after THC. Trends. Pharmacol. Sci. 36(5): 277–296.
   PubMed Web of Science ®Google Scholar
• Martyn, C. N., Illis, L. S., and Thom, J. 1995. Nabilone in the treatment of multiple sclerosis. Lancet. 345: 579.
   PubMed Web of Science ®Google Scholar
• Maurer, M., Henn, V., Dittrich, A., and Hofmann, A. 1990. Delta-9-THC shows antispastic and analgesic effects in a single case double blind trial. Eur. Arch. Psychiatry Clin. Neurosci. 240: 1–4.
   PubMed Web of Science ®Google Scholar
• McCabe, M., Smith, F. P., Goldberg, D., Macdonald, J., Woolley, P. V., and Warren, R. 1988. Efficacy of tetrahydrocannabinol in patients refractory to standard anti-emetic therapy. Invest. New Drugs. 6: 243–246.
   PubMed Web of Science ®Google Scholar
• Mechoulam, R. and Parker, L. A. 2013. The endocannabinoid system and the brain. Annu. Rev. Psychol. 64: 21–47.
   PubMed Web of Science ®Google Scholar
• Meiri, E., Jhangiani, H., Vredenburgh, J. J., Barbato, L. M., Carter, F. J., Yang, H. M., and Baranowski, V. 2007. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr. Med. Res. Opin. 23(3): 533–543.
   PubMed Web of Science ®Google Scholar
• Merritt, J. C., Crawford, W. J., Alexander, P. C., Anduze, A. L., and Gelbart, S. S. 1980. Effect of marihuana on intraocular and blood pressure in glaucoma. Ophthalmology 87(3): 222–228.
   PubMed Web of Science ®Google Scholar
• Merritt, J. C., Olsen, J. L., Armstrong, J. R., and McKinnon, S. M. 1981. Topical delta 9-tetrahydrocannabinol in hypertensive glaucomas. J. Pharm. Pharmacol. 33(1): 40–41.
   PubMed Web of Science ®Google Scholar
• Moore, T. H., Zammit, S., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., and Lewis, G. 2007. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370(9584): 319–328.
   PubMed Web of Science ®Google Scholar
• Mueller-Vahl, K. R., Schneider, U., Prevedel, H., Theloe, K., Kolbe, H., Daldrup, T., and Emrich, H. M. 2003. Delta-9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J. Clin. Psychiatry 64(4): 459–465.
   PubMed Web of Science ®Google Scholar
• Müller-Vahl, K. R., Schneider, U., Koblenz, A., Jobges, M., Kolbe, H., Daldrup, T., and Emrich, H. M. 2002. Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry 35(2): 57–61.
   PubMed Web of Science ®Google Scholar
• Müller-Vahl, K. R., Schneider, U., Prevedel, H., Theloe, K., Kolbe, H., Daldrup, T., and Emrich, H. M. 2003. Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J. Clin. Psychiatry 64(4): 459–465.
   PubMed Web of Science ®Google Scholar
• Naef, M., Curatolo, M., Petersen-Felix, S., Arendt-Nielsen, L., Zbinden, A., and Brenneisen, R. 2003. The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain 105(1–2): 79–88.
   PubMed Web of Science ®Google Scholar
• Naftali, T., Bar-Lev Schleider, L., Dotan, I., Lansky, E., Sklerovsky Benjaminov, F., and Konikoff, F. 2013. Cannabis induces a clinical response in patients with crohn's disease: a prospective placebo-controlled study. Clin. Gastroenterol. Hepatol. 11(10): 1276–1280.
   PubMed Web of Science ®Google Scholar
• Narang, S., Gibson, D., Wasan, A. D., Ross, E. L., Michna, E., Nedeljkovic, S. S., and Jamison, R. N. 2008. Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. J. Pain. 9(3): 254–264.
   PubMed Web of Science ®Google Scholar
• Neidhart, J. A., Gagen, M. M., Wilson, H. E., and Young, D. C. 1981. Comparative trial of the antiemetic effects of THC and haloperidol. J. Clin. Pharmacol. 21: 38–42.
   Web of Science ®Google Scholar
• Niederle, N., Schutte, J., and Schmidt, C. G. 1986. Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy. Klin. Wochenschr. 64: 362–365.
   PubMedGoogle Scholar
• Niiranen, A. and Mattson, K. 1985. A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy. Am. J. Clin. Oncol. 8: 336–340.
   PubMed Web of Science ®Google Scholar
• Notcutt, W., Price, M., Miller, R., Newport, S., Phillips, C., Simmons, S., and Sansom, C. 2004. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies. Anaesthesia 59(5): 440–452.
   PubMed Web of Science ®Google Scholar
• Notcutt. W., Langford, R., Davies, P., Ratcliffe, S., and Potts, R. 2012. A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols). Mult. Scler. 18(2): 219–228.
   PubMed Web of Science ®Google Scholar
• Novotna, A., Mares, J., Ratcliffe, S., Novakova, I., Vachova, M., Zapletalova, O., Gasperini, C., Pozzilli, C., Cefaro, L., Comi, G., Rossi, P., Ambler, Z., Stelmasiak, Z., Erdmann, A., Montalban, X., Klimek, A., and Davies, P. 2011. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex® ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur. J. Neurol. 18(9): 1122–1131.
   PubMed Web of Science ®Google Scholar
• Noyes, R., Brunk, S. F., Baram, D. A., and Canter, A. 1975. Analgesic effects of delta-9-THC. J. Clin. Pharmacol. 15: 139–143.
   PubMed Web of Science ®Google Scholar
• Noyes, R., Brunk, S. T., Avery, D. H., and Canter, A. 1975. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin. Pharmacol. Ther. 18: 84–89.
   PubMed Web of Science ®Google Scholar
• Nurmikko, T. J., Serpell, M. G., Hoggart, B., Toomey, P. J., Morlion, B. J., and Haines, D. 2007. Sativex successfully treats neuropathic pain characterised by allodynia: a randomized, double-blind, placebo-controlled clinical trial. Pain 133(1–3): 210–220.
   PubMed Web of Science ®Google Scholar
• Orr, L. E., McKernan, J. F., and Bloome, B. 1980. Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis. Arch. Intern. Med. 140: 1431–1433.
   PubMedGoogle Scholar
• Pertwee, R. 2014. Handbook of Cannabis. Oxford University Press, Oxford.
   Google Scholar
• Pertwee, R. G. 2010. Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr. Med. Chem. 17(14): 1360–1381.
   PubMed Web of Science ®Google Scholar
• Petro, D. J. and Ellenberger, C. 1981. Treatment of human spasticity with Δ9-tetrahydrocannabinol. J. Clin. Pharmacol. (Suppl 21): 413–416.
   Web of Science ®Google Scholar
• Pickering, E. E., Semple, S. J., Nazir, M. S., Murphy, K., Snow, T. M., Cummin, A. R., Moosavi, S., Guz, A., and Holdcroft, A. 2011. Cannabinoid effects on ventilation and breathlessness: a pilot study of efficacy and safety. Chron. Respir. Dis. 8(2): 109–118.
   PubMed Web of Science ®Google Scholar
• Pinsger, M., Schimetta, W., Volc, D., Hiermann, E., Riederer, F., and Polz, W. 2006. [Benefits of an add-on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain—a randomized controlled trial.] [Artikel in deutsch]. Wien. Klin. Wochenschr. 118(11–12): 327–335.
   PubMed Web of Science ®Google Scholar
• Pomeroy, M., Fennelly, J. J., and Towers, M. 1986. Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis. Cancer Chemother. Pharmacol. 17: 285–288.
   PubMed Web of Science ®Google Scholar
• Portenoy, R., Ganae-Motan, E., Allende, S., Yanagihara, R., Shaiova, L., Weinstein, S., McQuade, R., Wright, S., and Fallon, M. T. 2012. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J. Pain. 13(5): 438–449.
   PubMed Web of Science ®Google Scholar
• Raft, D., Gregg, J., Ghia, J., and Harris, L. 1977. Effects of intravenous tetrahydrocannabinol on experimental and surgical pain: psychological correlates of the analgesic response. Clin. Pharmacol. Ther. 21: 26–33.
   PubMed Web of Science ®Google Scholar
• Redmond, W. J., Goffaux, P., Potvin, S., and Marchand, S. 2008. Analgesic and antihyperalgesic effects of nabilone on experimental heat pain. Curr. Med. Res. Opin. 24(4): 1017–1024.
   PubMed Web of Science ®Google Scholar
• Regelson, W., Butler, J. R., Schulz, J., Kirk, T., Peek, L., Green, M. L., and Zalis, M. O. 1976. Delta-9-tetrahydrocannabinol as an effective antidepressant and appetite-stimulating agent in advanced cancer patients. In: Pharmacology of Marihuana. 2. pp. 763–776. Braude, M. C. and Szara, S., Eds., Raven Press, New York.
   Google Scholar
• Riggs, P. K., Vaida, F., Rossi, S. S., Sorkin, L. S., Gouaux, B., Grant, I., and Ellis, R. J. 2012. A pilot study of the effects of cannabis on appetite hormones in HIV-infected adult men. Brain Res. 1431: 46–52.
   PubMed Web of Science ®Google Scholar
• Rintala, D. H., Fiess, R. N., Tan, G., Holmes, S. A., and Bruel, B. M. 2010. Effect of dronabinol on central neuropathic pain after spinal cord injury: a pilot study. Am. J. Phys. Med. Rehabil. 89(10): 840–848.
   PubMed Web of Science ®Google Scholar
• Roberts, J. D., Gennings, C., and Shih, M. 2006. Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine. Eur. J. Pharmacol. 530(1–2): 54–58.
   PubMed Web of Science ®Google Scholar
• Rog, D. J., Nurmikko, T. J., Friede, T., and Young, C. A. 2005. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 65(6): 812–819.
   PubMed Web of Science ®Google Scholar
• Sallan, S. E., Cronin, C., Zelen, M., and Zinberg, N. E. 1980. Antiemetics in patients receiving chemotherapy for cancer. A randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. N. Engl. J. Med. 302: 135–138.
   PubMed Web of Science ®Google Scholar
• Sallan, S. E., Zinberg, N. E., and Frei, E. 1975. Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N. Engl. J. Med. 293: 795–797.
   PubMed Web of Science ®Google Scholar
• Schwarcz, G. and Karajgi, B. 2010. Improvement in refractory psychosis with dronabinol: four case reports. J. Clin. Psychiatry 71(11): 1552–1553.
   PubMed Web of Science ®Google Scholar
• Seeling, W., Kneer, L., Buchele, B., Gschwend, J. E., Maier, L., Nett, C., Simmet, T., Steffen, P., Schneider, M., and Rockemann, M. 2006. [(9)-tetrahydrocannabinol and the opioid receptor agonist piritramide do not act synergistically in postoperative pain.] [Article in German]. Anaesthesist 55(4): 391–400.
   PubMed Web of Science ®Google Scholar
• Selvarajah, D., Gandhi, R., Emery, C. J., and Tesfaye, S. 2010. Randomized placebo controlled double blind clinical trial of cannabis based medicinal product (sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care 33(1): 128–130.
   PubMed Web of Science ®Google Scholar
• Serpell, M., Ratcliffe, S., Hovorka, J., Schofield, M., Taylor, L., and Lauder, H. 2014. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. Eur. J. Pain 18(7): 999–1012.
   PubMed Web of Science ®Google Scholar
• Sieradzan, K. A., Fox, S. H., Hill, M., Dick, J. P., Crossman, A. R., and Brotchie, J. M. 2001. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology 57(11): 2108–2111.
   PubMed Web of Science ®Google Scholar
• Skrabek, R. Q., Galimova, L., Ethans, K., and Perry, D. 2008. Nabilone for the treatment of pain in fibromyalgia. J. Pain 9(2): 164–173.
   PubMed Web of Science ®Google Scholar
• Staquet, M., Gantt, C., and Machin, D. 1978. Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clin. Pharmacol. Ther. 23: 397–401.
   PubMed Web of Science ®Google Scholar
• Steele, N., Gralla, R. J., Braun, Jr. D. W., and Young, C. W. 1980. Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis. Cancer Treat. Rep. 64: 219–224.
   PubMedGoogle Scholar
• Strasser, F., Luftner, D., Possinger, K., Ernst, G., Ruhstaller, T., Meissner, W., Ko, Y. D., Schnelle, M., Reif, M., and Cerny, T. 2006. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-in-Cachexia-Study-Group. J. Clin. Oncol. 24(21): 3394–3400.
   PubMed Web of Science ®Google Scholar
• Struwe, M., Kaempfer, S. H., Geiger, C. J., Pavia, A. T., Plasse, T. F., Shepard, K. V., Ries, K., and Evans, T. G. 1993. Effect of dronabinol on nutritional status in HIV infection. Ann. Pharmacother. 27(7–8): 827–831.
   PubMed Web of Science ®Google Scholar
• Svendsen, K. B., Jensen, T. S., and Bach, F. W. 2004. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomized double blind placebo controlled crossover trial. BMJ 329(7460): 253.
   PubMed Web of Science ®Google Scholar
• Tomida, I., Azuara-Blanco, A., House, H., Flint, M., Pertwee, R. G. 2006. Robson, P. J. Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. J. Glaucoma. 15(5): 349–353.
   PubMed Web of Science ®Google Scholar
• Tomida, I., Azuara-Blanco, A., House, H., Flint, M., Pertwee, R. G., and Robson, P. J. 2006. Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. J. Glaucoma. 15(5): 349–353.
   PubMed Web of Science ®Google Scholar
• Ungerleider, J. T., Andrysiak, T., Fairbanks, L., Goodnight, J., Sarna, G., and Jamison, K. 1982. Cannabis and cancer chemotherapy. A comparison of oral delta-9-THC and prochlorperazine. Cancer 50: 636–645.
   PubMed Web of Science ®Google Scholar
• Ungerleider, J. T., Andyrsiak, T., Fairbanks, L., Ellison, G. W., and Myers, L. W. 1987. Δ9-THC in the treatment of spasticity associated with multiple sclerosis. Adv. Alcohol. Subst. Abuse. 7: 39–50.
   PubMedGoogle Scholar
• van den Elsen, G. A., Ahmed, A. I., Verkes, R. J., Kramers, C., Feuth, T., Rosenberg, P. B., van der Marck, M. A., and Olde Rikkert, M. G. 2015. Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: a randomized controlled trial. Neurology 84(23): 2338–2346.
   PubMed Web of Science ®Google Scholar
• Vandrey, R. G., Budney, A. J., Hughes, J. R., Liguori, A. 2008. A within-subject comparison of withdrawal symptoms during abstinence from cannabis, tobacco, and both substances. Drug. Alcohol. Depend. 92(1–3): 48–54.
   PubMed Web of Science ®Google Scholar
• Vaney, C., Heinzel-Gutenbrunner, M., Jobin, P., Tschopp, F., Gattlen, B., Hagen, U., Schnelle, M., and Reif, M. 2004. Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult. Scler. 10(4): 417–424.
   PubMed Web of Science ®Google Scholar
• Wada, J. K., Bogdon, D. L., Gunnell, J. C., Hum, G. J., Gota, C. H., and Rieth, T. E. 1982. Double-blind, randomized, crossover trial of nabilone vs. placebo in cancer chemotherapy. Cancer Treat. Rev. 9(Suppl B): 39–44.
   PubMed Web of Science ®Google Scholar
• Wade, D. T., Makela, P. M., House, H., Bateman, C., and Robson, P. 2006. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult. Scler. 12(5): 639–645.
   PubMed Web of Science ®Google Scholar
• Wade, D. T., Makela, P., Robson, P., House, H., and Bateman, C. 2004. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult. Scler. 10(4): 434–441.
   PubMed Web of Science ®Google Scholar
• Wade, D. T., Robson, P., House, H., Makela, P., and Aram, J. 2003. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin. Rehabil. 17: 18–26.
   Web of Science ®Google Scholar
• Wade, D. T., Robson, P., House, H., Makela, P., Aram, J. 2003. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin. Rehabil. 17: 18–26.
   Web of Science ®Google Scholar
• Wade, D. T., Robson, P., House, H., Makela, P., and Aram, J. 2003. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin. Rehabil. 17: 18–26.
   Web of Science ®Google Scholar
• Wallace, M. S., Marcotte, T. D., Umlauf, A., Gouaux, B., and Atkinson, J. H. 2015. Efficacy of Inhaled Cannabis on Painful Diabetic Neuropathy. J. Pain. 16(7): 616–627.
   PubMed Web of Science ®Google Scholar
• Wallace, M., Schulteis, G., Atkinson, J. H., Wolfson, T., Lazzaretto, D., Bentley, H., Gouaux, B., and Abramson, I. 2007. Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. Anesthesiology 107(5): 785–796.
   PubMed Web of Science ®Google Scholar
• Ware, M. A., Ducruet, T., and Robinson, A. R. 2006. Evaluation of herbal cannabis characteristics by medical users: a randomized trial. Harm Reduct J. 3(1): 32.
   PubMedGoogle Scholar
• Ware, M. A., Wang, T., Shapiro, S., Robinson, A., Ducruet, T., Huynh, T., Gamsa, A., Bennett, G. J., and Collet, J. P. 2010. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ 182(14): E694–E701.
   PubMed Web of Science ®Google Scholar
• Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., Schmidlkofer, S., Westwood, M., and Kleijnen, J. 2015. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 313(24): 2456–2473.
   PubMed Web of Science ®Google Scholar
• Wilsey, B., Marcotte, T., Deutsch, R., Gouaux, B., Sakai, S., and Donaghe, H. 2013. Low-dose vaporized cannabis significantly improves neuropathic pain. J. Pain 14(2): 136–148.
   PubMed Web of Science ®Google Scholar
• Wilsey, B., Marcotte, T., Tsodikov, A., Millman, J., Bentley, H., Gouaux, B., and Fishman, S. 2008. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J. Pain 9(6): 506–521.
   PubMed Web of Science ®Google Scholar
• Wissel, J., Haydn, T., Müller, J., Brenneis, C., Berger, T., Poewe, W., and Schelosky, L. D. 2006. Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain: a double-blind placebo-controlled cross-over trial. J. Neurol. 253(10): 1337–1341.
   PubMed Web of Science ®Google Scholar
• Wong, B. S., Camilleri, M., Busciglio, I., Carlson, P., Szarka, L. A., Burton, D., and Zinsmeister, A. R. 2011. Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome. Gastroenterology 141(5): 1638–1647.
   PubMed Web of Science ®Google Scholar
• Wong, B., Camilleri, M., Busciglio, I., Carlson, P., Szarka, L., Burton, D., and Zinsmeister, A. R. 2011. Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome. Gastroenterology 141(5): 1638–1647.
   PubMed Web of Science ®Google Scholar
• Wong, B., Camilleri, M., Busciglio, I., Carlson, P., Szarka, L., Burton, D., and Zinsmeister, A. R. 2012. Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea. Neurogastroenterol Motil. 24(4): 358–e169.
   PubMed Web of Science ®Google Scholar
• Zajicek, J., Ball, S., Wright, D., Vickery, J., Nunn, A., and Miller, D. 2013. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomized, placebo-controlled trial. Lancet Neurol. 12(9): 857–865.
   PubMed Web of Science ®Google Scholar
• Zajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A., and Thompson, A., on behalf of the UK MS Research Group. 2003. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomized placebo-controlled trial. Lancet 362(9385): 1517–1526.
   PubMed Web of Science ®Google Scholar